HRQoL in Patients with Solid Tumors Treated with Hadrontherapy

Launched by CNAO NATIONAL CENTER OF ONCOLOGICAL HADRONTHERAPY · Jul 7, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the quality of life in patients with head and neck, skull base, and brain cancers who are treated with a specialized cancer treatment called hadrontherapy. The researchers want to understand how this treatment affects patients' everyday lives and well-being, as there is limited information on this topic. The trial includes two groups: one group consists of survivors who have been cancer-free for at least five years, and the other group includes patients who are currently receiving hadrontherapy with the hope of curing their cancer.

To participate, patients need to be at least 18 years old and able to give their consent. Survivors must not have any signs of cancer returning, while current patients must have a confirmed diagnosis and be suitable for treatment. Participants will fill out specific questionnaires to share their experiences and feelings about their quality of life throughout the trial. It's important to note that those with certain psychiatric or neurological conditions, or who have had previous cancer treatments, may not be eligible to join. Overall, this study aims to gather valuable information that could help improve care and support for patients undergoing hadrontherapy.

Gender

ALL

Eligibility criteria

• Cohort A ("survivors"):
• • Inclusion Criteria
• • Patients with at least a follow up of 5 years with head and neck, skull base and brain tumors and no evidence of progressive disease.
• • The patient is able to give consent
• Exclusion Criteria:
• • Re-irradiation.
• • Second tumor.
• • Known cases of any psychiatric and neurological diseases leading to disability (eg, manic disorder, schizophrenia etc..), which could impair compilation of questionnaires or affect quality of life.
• Cohort B:
• Inclusion Criteria:
• • Histological and/or radiological diagnosis of head and neck tumors
• • Patients candidate for curative intent hadrontherapy
• • Patients ≥ 18 years of age
• • The patient is able to give consent
• Exclusion criteria:
• • Re-irradiation.
• • Second tumor
• • Known cases of any psychiatric and neurological diseases leading to disability (eg, manic disorder, schizophrenia etc..), which could impair compilation of questionnaires or affect quality of life
• • Presence of diffused metastasis